DOCSLIB.ORG

Small Molecule Inhibitors of Protein-Protein Interactions By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Small Molecule Inhibitors of Protein-Protein Interactions By Small Molecule Inhibitors of Protein-Protein Interactions by Kareem Khoury Bachelor of Science, University of Pittsburgh, 2008 Submitted to the Graduate Faculty of School of Pharmacy in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2013 UNIVERSITY OF PITTSBURGH SCHOOL OF PHARMACY This dissertation was presented by Kareem Khoury It was defended on December 5th, 2013 and approved by Barry I. Gold, Professor, Department of Pharmaceutical Sciences Xiang-Qun Xie, Professor, Department of Pharmaceutical Sciences Song Li, Professor, Department of Pharmaceutical Sciences Carlos Camacho, Department of Structural Biology Dissertation Advisor: Alexander Doemling, Professor, Department of Pharmaceutical Sciences ii Copyright © by Kareem Khoury 2013 iii Discovery of Small Molecule Inhibitors for Protein-Protein Interactions Kareem Khoury, PhD University of Pittsburgh, 2013 Protein-protein interactions (PPIs) constitute a rising class of targets for the next generation of therapeutic intervention. Though they play a fundamental role in many biological processes and almost all pathological conditions including cancer, diabetes, and autoimmune diseases, , PPIs remain underrepresented in drug discovery. Small molecules are the ideal candidates for PPI inhibitors due to low production cost and better absorption, distribution, metabolism, and excretion (ADME) properties compared to biological agents. Discovering small molecule inhibitors of PPIs has proven to be difficult because of the relatively large contact areas between proteins. Herein are described novel approaches to the chemical synthesis as well as a screening tool which will facilitate the discovery of small molecule inhibitors of PPIs. Currently, molecules derived from multicomponent reactions (MCRs) are rarely distributed in general screening libraries. The exceptions are special scaffolds, e.g. dihydropyrimidines, whose class includes the blockbuster Ca antagonist, Nifedipine. Interestingly, however, MCR molecules have been frequently described as inhibitors of PPIs. Examples include p53/mdm21,2, Bcl23, HIV-1/gp414, CCR55 and oxytocin antagonists6. These findings support the notion that MCR molecules are especially suitable for mimicking peptides. We have developed a virtual library of scaffolds derived from a diverse set of MCRs which are easily chemically accessible. iv In addition, our lab has set forth to discover novel MCRs to add to our virtual library. One such scaffold described in this dissertation is derived from the Ugi-4-component-5- cenetered reaction. A novel amidation of this classic scaffold adds a true four-component reaction to our MCR database. The scope and limitations of this reaction are described in detail allowing for an accurate representation of compounds with a high probability of being synthesized. Various cyclizations of this scaffold are also explored and described in detail. A receptor-based drug discovery approach can be applied when an accurate three- dimensional (3D) structure of a specific PPI complex is available. A novel, complementary and transformative docking approach for the rational design of small molecule inhibitors was developed for our virtual library based on the “anchor” concept. Applying our method, we efficiently discovered several new scaffolds of inhibitors of the p53/MDM2 interaction with lower micromolar affinity binding to MDM2, which can serve as starting point for medicinal chemistry optimization. In summary, the methods and tools described in this dissertation are important contributions to the fields of medicinal chemistry and structure-based drug discovery because they combine structural insights and ligand design to expedite the discovery of novel small molecule inhibitors of PPIs. v TABLE OF CONTENTS LIST OF SCHEMES ............................................................................................................... XIII PREFACE ................................................................................................................................. XIV 1.0 INTRODUCTION ........................................................................................................ 1 1.1 PROTEIN-PROTEIN INTERACTIONS AS DRUG TARGETS ................... 1 1.2 THE P53/MDM2 AXIS ....................................................................................... 3 1.2.1 p53/MDM2 Biology.......................................................................................... 4 1.2.2 p53/MDM2 interactions .................................................................................. 8 1.2.3 Small molecule-MDM2 co-crystals .............................................................. 10 1.2.4 MDMX-co crystal .......................................................................................... 21 1.2.5 Clinical Trials ................................................................................................. 24 2.0 ANCHORQUERY: AN EASILY ACCESSIBLE VIRTUAL SCREENING LIBRARY/TOOL ....................................................................................................................... 26 2.1 COMPOUND SCREENING LIBRARY GENERATION ............................. 33 2.1.1 Isocyanide Based MCRs ................................................................................ 34 2.1.1.1 Ugi Reaction......................................................................................... 34 2.1.1.2 Tetrazole Reaction .............................................................................. 35 2.1.1.3 Hydantoine Reaction........................................................................... 37 2.1.1.4 Imidazole .............................................................................................. 38 vi 2.1.1.5 Diketopiperazine ................................................................................. 39 2.1.1.6 Praziquantel (Ugi/Pictet-Spengler) .................................................... 40 2.1.1.7 Ugi 4-component-5-centered reaction ............................................... 42 2.1.1.8 Ugi-deprotective Cyclization - Benzimidazole .................................. 43 2.1.1.9 Ugi-deprotective Cyclization - Dihydrobenzodiazepine-acetamide 45 2.1.1.10 Ugi-deprotective Cyclization - Tetrahydrobenzodiazepine - carboxamide ....................................................................................................... 46 2.1.1.11 Ugi- deprotective Cyclization - Dihydrobenzodiazepine- carboxamide ....................................................................................................... 47 2.1.1.12 Ugi- deprotective Cyclization - Tetrazolyl- dihydrobenzodiazepine….................................................................................. 49 2.1.1.13 Groebke/Blackburn/Bienayme ........................................................ 50 2.1.1.14 Thienodiazepine ................................................................................ 51 2.1.1.15 Orru .................................................................................................... 53 2.1.1.16 Schöllkopf reaction ........................................................................... 54 2.1.1.17 Thiazole Amidation ........................................................................... 56 2.1.2 Non-Isocyanide Based Multicomponent Reactions .................................... 58 2.1.2.1 Döbner .................................................................................................. 58 2.1.2.2 Gewald.................................................................................................. 59 2.1.2.3 Isoquinoline Amidation ...................................................................... 61 2.1.2.4 Reaction mapping and smarts codes ................................................. 62 2.1.3 Principal Moment of Inertia ......................................................................... 68 2.2 ANCHORQUERY IMPLEMENTATION ...................................................... 70 vii 3.0 DISCOVERY OF NEW MULTICOMPONENT REACTIONS FOR VIRTUAL SCREENING ............................................................................................................................... 74 3.1 IMINODICARBOXAMIDES BY VARIATION OF THE UGI-4- COMPONENT-5-CENTERED REACTION .................................................................. 75 3.1.1 Materials and Methods ................................................................................. 85 3.2 CYCLIZATION SCAFFOLDS BY VARIATION OF THE UGI-4- COMPONENT-5-CENTERED REACTION ................................................................ 105 3.2.1 Isoindolinone ................................................................................................ 107 3.2.2 Dioxopyrrolidines ........................................................................................ 110 3.2.3 Pictet-Spengler ............................................................................................. 113 3.2.4 Materials and Methods ............................................................................... 121 4.0 UGI-4-COMPONENT-5-CENTERED REACTION FOR USE IN P53/MDM2 155 4.1 ANCHORQUERY SEARCH AGAINST P53/MDM2 ................................. 155 4.2 SYNTHESIS AND IN VITRO ACTIVITY OF SELECTED COMPOUNDS 158 4.2.1 Materials and Methods ............................................................................... 164 4.3 CO-CRYSTAL AND CELL BASED SCREENING .................................... 181 4.3.1 Materials and Methods ..............................................................................
Load more

Recommended publications
  • 1 Randomized Trials of Retosiban Versus Placebo Or Atosiban In
    Randomized trials of retosiban versus placebo or atosiban in spontaneous preterm labor George Saade MDa, Andrew Shennan MDb, Kathleen J Beach MDc,1, Eran Hadar MDd, Barbara V Parilla MDe,2, Jerry Snidow PharmDf,3, Marcy Powell MDg, Timothy H Montague PhDh, Feng Liu PhDh,4, Yosuke Komatsu MDi,5, Laura McKain MDj,6, Steven Thornton DMk aDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA; bDepartment of Women and Children’s Health, King’s College London, St Thomas’ Hospital, London, UK; cDepartment of Maternal and Fetal Medicine, GSK, Research Triangle Park, NC, USA; dHelen Schneider Hospital for Women, Rabin Medical Center, Petach-Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; eDepartment of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park Ridge, IL, USA; fAlternative Discovery and Development, GSK, Research Triangle Park, NC, USA; gCentral Safety Department, GSK, Research Triangle Park, NC, USA; hClinical Statistics, Quantitative Sciences, GSK, Collegeville, PA, USA; iMaternal and Neonatal Health Unit, Alternative Discovery & Development, R&D, GSK, Research Triangle Park, NC, USA; jPharmacovigilance, PPD, Wilmington, NC, USA; kBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK 1At the time of the trial; 2At the time of the trial, present address: Rush Center for Maternal- Fetal Medicine, Aurora, IL, USA; 3At the time of the trial; 4At the time of the trial, present address: AstraZeneca,
    [Show full text]
  • 1 the Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the 2 Response of Human Myometrial Explants to Prolonged Mechanical Stretch
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Apollo 1 The effect of an oxytocin receptor antagonist (retosiban, GSK221149A) on the 2 response of human myometrial explants to prolonged mechanical stretch. 3 4 Alexandros A. Moraitis, Yolande Cordeaux, D. Stephen Charnock-Jones, Gordon C. S. 5 Smith. 6 Department of Obstetrics and Gynaecology, University of Cambridge; NIHR Cambridge 7 Comprehensive Biomedical Research Centre, CB2 2SW, UK. 8 9 Abbreviated title: Retosiban and myometrial contractility. 10 Key terms: Retosiban, myometrial contractility, preterm birth, multiple pregnancy, oxytocin 11 receptor. 12 Word count: 2203 13 Number of figures: 3 14 15 Correspondending author and person to whom reprint requests should be addressed: 16 Gordon CS Smith. Department of Obstetrics and Gynaecology, University of Cambridge, 17 The Rosie Hospital, Cambridge, CB2 0SW, UK. 18 Tel: 01223 763888/763890; Fax: 01223 763889; 19 E-mail: [email protected] 20 21 Disclosure statement: 22 GS receives/has received research support from GE (supply of two diagnostic ultrasound 23 systems) and Roche (supply of equipment and reagents for biomarker studies). GS has 24 been paid to attend advisory boards by GSK and Roche. GS has acted as a paid consultant 25 to GSK. GS is named inventor in a patent submitted by GSK (UK), for the use of retosiban to 26 prevent preterm birth in multiple pregnancy (PCT/EP2014/062602), based on the work 27 described in this paper. GS and DSCJ have been awarded £199,413 to fund further 28 research on retosiban by GSK. AM has received a travel grant by GSK to present at the 1 29 Society of Reproductive Investigation (SRI) annual conference in March 2015.
    [Show full text]
  • Molecular Basis of Ligand Recognition and Activation of Human V2 Vasopressin Receptor
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427077; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor Fulai Zhou1, 12, Chenyu Ye2, 12, Xiaomin Ma3, 12, Wanchao Yin1, Qingtong Zhou4, Xinheng He1, 5, Xiaokang Zhang6, 7, Tristan I. Croll8, Dehua Yang1, 5, 9, Peiyi Wang3, 10, H. Eric Xu1, 5, 11, Ming-Wei Wang1, 2, 4, 5, 9, 11, Yi Jiang1, 5, 1. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2. School of Pharmacy, Fudan University, Shanghai 201203, China 3. Cryo-EM Centre, Southern University of Science and Technology, Shenzhen 515055, China 4. School of Basic Medical Sciences, Fudan University, Shanghai 200032, China 5. University of Chinese Academy of Sciences, 100049 Beijing, China 6. Interdisciplinary Center for Brain Information, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; 7. Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China 8. Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK 9. The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China 10. Department of Biology, Southern University of Science and Technology, Shenzhen 515055, China 11. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China 12. These authors contributed equally: Fulai Zhou, Chenyu Ye, and Xiaomin Ma.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Molecular Basis of Ligand Recognition and Activation of Human V2 Vasopressin Receptor
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427077; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor Fulai Zhou1, 12, Chenyu Ye2, 12, Xiaomin Ma3, 12, Wanchao Yin1, Qingtong Zhou4, Xinheng He1, 5, Xiaokang Zhang6, 7, Tristan I. Croll8, Dehua Yang1, 5, 9, Peiyi Wang3, 10, H. Eric Xu1, 5, 11, Ming-Wei Wang1, 2, 4, 5, 9, 11, Yi Jiang1, 5, 1. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2. School of Pharmacy, Fudan University, Shanghai 201203, China 3. Cryo-EM Centre, Southern University of Science and Technology, Shenzhen 515055, China 4. School of Basic Medical Sciences, Fudan University, Shanghai 200032, China 5. University of Chinese Academy of Sciences, 100049 Beijing, China 6. Interdisciplinary Center for Brain Information, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; 7. Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China 8. Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK 9. The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China 10. Department of Biology, Southern University of Science and Technology, Shenzhen 515055, China 11. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China 12. These authors contributed equally: Fulai Zhou, Chenyu Ye, and Xiaomin Ma.
    [Show full text]
  • Directed Evolution for High Functional Production and Stability of a Challenging G Protein‑Coupled Receptor Yann Waltenspühl, Jeliazko R
    www.nature.com/scientificreports OPEN Directed evolution for high functional production and stability of a challenging G protein‑coupled receptor Yann Waltenspühl, Jeliazko R. Jeliazkov, Lutz Kummer & Andreas Plückthun* Membrane proteins such as G protein‑coupled receptors (GPCRs) carry out many fundamental biological functions, are involved in a large number of physiological responses, and are thus important drug targets. To allow detailed biophysical and structural studies, most of these important receptors have to be engineered to overcome their poor intrinsic stability and low expression levels. However, those GPCRs with especially poor properties cannot be successfully optimised even with the current technologies. Here, we present an engineering strategy, based on the combination of three previously developed directed evolution methods, to improve the properties of particularly challenging GPCRs. Application of this novel combination approach enabled the successful selection for improved and crystallisable variants of the human oxytocin receptor, a GPCR with particularly low intrinsic production levels. To analyse the selection results and, in particular, compare the mutations enriched in diferent hosts, we developed a Next‑Generation Sequencing (NGS) strategy that combines long reads, covering the whole receptor, with exceptionally low error rates. This study thus gave insight into the evolution pressure on the same membrane protein in prokaryotes and eukaryotes. Our long‑ read NGS strategy provides a general methodology for the highly accurate analysis of libraries of point mutants during directed evolution. G protein-coupled receptors (GPCRs) play crucial roles in human physiology1,2. Tis biological importance is further refected in their therapeutic relevance. As such, GPCRs constitute the largest class of single drug targets, with an estimated 35% of marketed FDA approved drugs acting through these receptors3,4.
    [Show full text]
  • Oxytocin Receptor OXTR
    Oxytocin Receptor OXTR The oxytocin receptor belongs to the G-protein-coupled seven-transmembrane receptor superfamily. Its main physiological role is regulating the contraction of uterine smooth muscle at parturition and the ejection of milk from the lactating breast. The oxytocin receptors are activated in response to binding oxytocin and a similar nonapeptide, vasopressin. Oxytocin receptor triggers Gi or Gq protein-mediated signaling cascades leading to the regulation of a variety of neuroendocrine and cognitive functions. Oxytocin is a nonapeptide of the neurohypophyseal protein family that binds specifically to the oxytocin receptor to produce a multitude of central and peripheral physiological responses. In vivo, oxytocin acts as a paracrine and/or autocrine mediator of multiple biological effects. These effects are exerted primarily through interactions with G-protein-coupled oxytocin/vasopressin receptors, which, via Gq and Gi, stimulate phospholipase C-mediated hydrolysis of phosphoinositides. www.MedChemExpress.com 1 Oxytocin Receptor Agonists & Antagonists Atosiban Atosiban acetate (RW22164; RWJ22164) Cat. No.: HY-17572 (RW22164 acetate; RWJ22164 acetate) Cat. No.: HY-17572A Atosiban (RW22164; RWJ22164) is a nonapeptide Atosiban acetate (RW22164 acetate;RWJ22164 competitive vasopressin/oxytocin receptor acetate) is a nonapeptide competitive antagonist, and is a desamino-oxytocin analogue. vasopressin/oxytocin receptor antagonist, and is a Atosiban is the main tocolytic agent and has the desamino-oxytocin analogue. Atosiban is the main potential for spontaneous preterm labor research. tocolytic agent and has the potential for spontaneous preterm labor research. Purity: 99.09% Purity: 99.92% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Carbetocin Epelsiban Cat.
    [Show full text]
  • Leopold Dürrauer Masterarbeit Biologische Chemie
    MASTERARBEIT / MASTER’S THESIS Title der Masterarbeit / Title of the Master’s Thesis Characterisation of selective human oxytocin/ vasopressin ligands submitted by Leopold Dürrauer, BSc Angestrebter akademischer Grad / in partial fulfilment of the requirements for the degree of Master of Science (MSc) Wien, 2018 / Vienna, 2018 degree program code as it appears on A 066 863 the student record sheet: degree program as it appears on Biologische Chemie the student record sheet: Supervisor: Assoc. Prof. Priv.-Doz. Dr. Christian Gruber, PhD Masterarbeit Biologische Chemie ii Characterisation of selective human oxytocin/vasopressin ligands Acknowledgment I would like to thank Christian Gruber, for believing in me and providing me with the oppor- tunity to carry out this thesis on the other side of the globe. I would also like to thank Peter Keov for his invaluable practical support, Ester Aeiye Odukunle for sharing her asterotocin results, Markus Muttenthaler for synthesis of the peptides used dur- ing this thesis, and Yoonseong Park for his valuable insights into mite oxytocin/vasopressin- like peptide receptors. And, last but not least, I would like to thank my family and friends for their outstanding and unconditional support. 1 Masterarbeit Biologische Chemie 2 Masterarbeit Biologische Chemie Table of Contents Acknowledgment ....................................................................................................................... 1 Table of Contents ......................................................................................................................
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update Horizon
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: April 2015 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290-2010-00006-C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 April 2015 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290-2010-00006-C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]
  • Myometrial Cytokines and Their Role in the Onset of Labour
    231 3 S P Sivarajasingam and others Inflammatory signalling in 231:3 R101–R119 Review human labour Myometrial cytokines and their role in the onset of labour Correspondence S P Sivarajasingam1, N Imami2 and M R Johnson1 should be addressed to M R Johnson 1Department of Surgery and Cancer, Imperial College London, Chelsea and Westminster Hospital, London, UK Email 2Department of Medicine, Imperial College London, London, UK [email protected] Abstract Human labour is an inflammatory event, physiologically driven by an interaction Key Words between hormonal and mechanical factors and pathologically associated with f inflammatory diseases infection, bleeding and excessive uterine stretch. The initiation and communicators of f labour inflammation is still not completely understood; however, a key role for cytokines has f cytokines been implicated. We summarise the current understanding of the nature and role of f reproduction cytokines, chemokines and hormones and their involvement in signalling within the myometrium particularly during labour. Journal of Endocrinology (2016) 231, R101–R119 Endocrinology of Introduction Myometrial inflammation Journal Human labour is an inflammatory event, physiologically Inflammation typically involves white cell infiltration driven by an interaction between hormonal and and the production of cytokines that induce changes in mechanical factors and pathologically associated cell function through the modulation of gene expression. with infection, bleeding and excessive uterine stretch It is a highly coordinated process designed to protect (Golightly et al. 2011). However, the processes involved are the organism from infection (Meeusen et al. 2001, not fully understood, especially the triggers/activators of Martinon et al. 2009), but can be induced by other stimuli labour.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub
    US 20160354315A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub. Date: Dec. 8, 2016 (54) DOSAGE FORMS AND USE THEREOF Publication Classification (71) Applicant: Triastek, Inc., Nanjing (CN) (51) Int. Cl. A69/20 (2006.01) (72) Inventor: Xiaoling Li, Dublin, CA (US) A6IR 9/24 (2006.01) A63L/92 (2006.01) (52) U.S. Cl. (21) Appl. No.: 15/173,596 CPC ........... A61K 9/2031 (2013.01); A61K 9/2027 (2013.01); A61K 31/192 (2013.01); A61 K 9/209 (2013.01) (22) Filed: Jun. 3, 2016 (57) ABSTRACT The present disclosure provides a stable solid pharmaceuti Related U.S. Application Data cal dosage form for oral administration. The dosage form includes a Substrate that forms at least one compartment and (60) Provisional application No. 62/170,645, filed on Jun. a drug content loaded into the compartment. The dosage 3, 2015, provisional application No. 62/313,092, filed form is so designed that the active pharmaceutical ingredient on Mar. 24, 2016. of the drug content is released in a controlled manner. Patent Application Publication Dec. 8, 2016 Sheet 1 of 20 US 2016/0354315 A1 FG. A F.G. B. Peak carcetitration, tax ise F.G. C Patent Application Publication Dec. 8, 2016 Sheet 2 of 20 US 2016/0354315 A1 F.G. 2B Patent Application Publication Dec. 8, 2016 Sheet 3 of 20 US 2016/0354315 A1 F.G. 3 Patent Application Publication Dec. 8, 2016 Sheet 4 of 20 US 2016/0354315 A1 Patent Application Publication Dec.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]